Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H23Cl2N3OS.ClH |
| Molecular Weight | 484.869 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCN(CC1)C2=CC=CC=C2\C=C3/SCCN(C3=O)C4=CC=C(Cl)C(Cl)=C4
InChI
InChIKey=NMTRXBJYASHMND-UXTSPRGOSA-N
InChI=1S/C22H23Cl2N3OS.ClH/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17;/h2-7,14-15H,8-13H2,1H3;1H/b21-14-;
| Molecular Formula | C22H23Cl2N3OS |
| Molecular Weight | 448.409 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Elzasonan (CP 448187) is a serotonin 1B/1D receptor antagonist. Elzasonan was primarily metabolized via oxidative N‐demethylation, N‐oxidation, and aryl hydroxylation. Pfizer was developing elzasonan for the treatment of anxiety and affective disorders however development has been discontinued.
CNS Activity
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:02:04 GMT 2025
by
admin
on
Mon Mar 31 18:02:04 GMT 2025
|
| Record UNII |
X38F62RR8L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Mon Mar 31 18:02:04 GMT 2025 , Edited by admin on Mon Mar 31 18:02:04 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2110932
Created by
admin on Mon Mar 31 18:02:04 GMT 2025 , Edited by admin on Mon Mar 31 18:02:04 GMT 2025
|
PRIMARY | |||
|
X38F62RR8L
Created by
admin on Mon Mar 31 18:02:04 GMT 2025 , Edited by admin on Mon Mar 31 18:02:04 GMT 2025
|
PRIMARY | |||
|
C73806
Created by
admin on Mon Mar 31 18:02:04 GMT 2025 , Edited by admin on Mon Mar 31 18:02:04 GMT 2025
|
PRIMARY | |||
|
220322-05-4
Created by
admin on Mon Mar 31 18:02:04 GMT 2025 , Edited by admin on Mon Mar 31 18:02:04 GMT 2025
|
PRIMARY | |||
|
300000044593
Created by
admin on Mon Mar 31 18:02:04 GMT 2025 , Edited by admin on Mon Mar 31 18:02:04 GMT 2025
|
PRIMARY | |||
|
MM-16
Created by
admin on Mon Mar 31 18:02:04 GMT 2025 , Edited by admin on Mon Mar 31 18:02:04 GMT 2025
|
PRIMARY | |||
|
205683-38-1
Created by
admin on Mon Mar 31 18:02:04 GMT 2025 , Edited by admin on Mon Mar 31 18:02:04 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
6506051
Created by
admin on Mon Mar 31 18:02:04 GMT 2025 , Edited by admin on Mon Mar 31 18:02:04 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |